Camlin Fine Sciences Limited (CAMLINFINE) fair value: what the stock is really worth
As of Sep 25, 2026: fair value of Camlin Fine Sciences Limited ₹24.45, price ₹97.30, upside -74.9%, quality 31 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.
Watch Camlin Fine Sciences Limited for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card.Watch for freePro now: $1 first month
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Sep 27, 2026.
How to read this chart
60‑month range ₹86.95 – ₹327.53 · fair‑value band ₹19.20 – ₹30.56 · the ₹97.30 price screens above the ₹24.45 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Sep 27, 2026.
Follow Camlin Fine Sciences in your weekly email
Every Wednesday you see whether Camlin Fine Sciences is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Camlin Fine Sciences Limited, together with its subsidiaries, research, develops, manufactures, and markets specialty chemicals, ingredients, and additive blend products in India and internationally.
Show more
Camlin Fine Sciences Limited, together with its subsidiaries, research, develops, manufactures, and markets specialty chemicals, ingredients, and additive blend products in India and internationally. The company offers shelf-life solutions, which include basic ingredients, such as tert-butylhydroquinone (TBHQ), Butylated Hydroxyanisole (BHA), Butylated Hydroxytoluene (BHT), and Ascorbyl Palmitate (ASP); aroma ingredients, including vanillin and ethyl vanillin, natural vanillin, and some of its combinations; performance chemicals that include Hydroquinone (HQ), Catechol (CAT), Monomethyl Ether of HQ (MEHQ), tert butylcatechol (TBC), Guaiacol, and Veratrole; and health and wellness products comprising algae based products, such as Omega 3 fatty acids. It sells its prodycrts under the Xtendra, Nasure, Ezential, adorr, Dinamic, and Biosus brands. The company's products are used in food and beverage, pet food and rendering, animal nutrition, petrochemical, nutrition and health, biofuel, agrochemical, pharmaceutical, polymers, fragrance and flavor, and dyes and pigments industries. The company was formerly known as Camlin Fine Chemicals Ltd. and changed its name to Camlin Fine Sciences Limited in August 2011. Camlin Fine Sciences Limited was founded in 1931 and is headquartered in Mumbai, India.
Stock analysis
Camlin Fine Sciences Limited (CAMLINFINE) currently trades at ₹97.30, while our model-based Fair Value estimate is ₹24.45, implying the stock looks roughly 297.9% overvalued today.
Show more
Valuation
Bull case: the DCF Models group reads highest at a median of ₹78.26 per share, and 0 of the 15 models we run sit above the ₹97.30 price.
Bear case: the Earnings-Based group reads lowest at ₹20.62, and 15 of the 15 models stay below the price. Evidence for this calculation is medium.
Scenario range: ₹19.20 (bear) to ₹30.56 (bull), the price of ₹97.30 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 31/100 (below-average quality), in the Basic Materials sector.
Expensive Growth: The company is growing, but growth may require heavy reinvestment or weak cash conversion.
Camlin Fine Sciences Limited reported revenue of ₹17.2B in FY2026 versus ₹14.0B in FY2022, a compound +5.2%/yr. Reported net income was ₹276M in FY2026, compounding −17.9%/yr from FY2022.
Key figures
Market cap ₹26.1B (≈ $273M) · P/S ratio 1.52 · EPS (TTM) ₹−1.60 · Net margin 1.6% · Return on equity −3.4% · Return on assets (EBIT) 5.2% · Operating margin 0.1% · Revenue (TTM) ₹17.2B.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 32 out of 100 (medium confidence).
What moves the price
The share trades about 56% below its 52-week high and 1% above its 52-week low, currently below its 200-day average.
For context, the median of 10 Basic Materials peers we cover trades at −54% fair-value upside, at −75%, CAMLINFINE screens richer than that median.
Fair Value models
Bear ₹19.20Fair Value ₹24.45Bull ₹30.56
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.44/100
The company is growing, but growth may require heavy reinvestment or weak cash conversion.
Revenue growth 1 year
+3.4%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+0.8%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+7.9%
Start year 2021 (pandemic). Over 10 years: +13.4% a year
Revenue growth 19 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+20.9%
’15
’16
’17
’18
’19
’20
’21
’22
’23
’24
’25
’26
What shareholders gained per year (last 5 years), in INR ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate. Measured in INR: this currency has depreciated against the euro and dollar over the long run, so part of the nominal rate is currency erosion that never reaches a EUR/USD investor.
−17.1%
Earnings growth per share plus dividend.
Earnings per share, growth per year−17.1%
Dividend (yield on the price)0.0%
Pace: 5 vs 10 years ⓘTwo data points, not a trend model: earnings growth per share over the last 5 fiscal years against the last 10. Labelled "steady" when both rates are within 3 percentage points of each other, otherwise picking up or flattening. Shown only when ten years of history exist.−17.1% vs −11.2%, slowing
Profit margin 2021 to 2026 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.14% → 1%
Compare Camlin Fine Sciences Limited with another stock
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Specialty Chemicals · 707 stocks
Beats the industry median on 2/9 measures
Overall it trails its industry peers.
Valuation
Quality Score31 · Bottom 25%
Fair Value upside−74.9% · Bottom 25%
Profitability
Return on assets1.0% · Below median
Net margin (TTM)1.6% · Below median
Operating margin (TTM)0.1% · Bottom 25%
Growth and dividend
Revenue growth−2.9% · Below median
Balance sheet
Debt / equity0.29× · Above median
Valuation Multiplesvs Specialty Chemicals median · lower = cheaper
P/S (TTM)0.02× · Cheapest 25%
EV/EBITDA1.6× · Cheapest 25%
Strength profile in five axes (Snowflake)
This stockSector peers
VALUE (fair-value potential)0· sector 0
FUTURE (revenue growth)0· sector 28
PAST (return on equity)0· sector 23
HEALTH (low debt)85· sector 95
DIVIDEND (yield)0· sector 30
VALUE 0: the price sits above our fair-value range.
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Cite: Fair Value Calculator (2026). "Camlin Fine Sciences Limited Fair Value". https://www.fairvalue-calculator.com/stock/CAMLINFINE
Frequently asked questions
Is Camlin Fine Sciences Limited (CAMLINFINE) overvalued or undervalued?
As of Sep 27, 2026, our model estimates a fair value of ₹24.45 versus a price of ₹97.30, about −75% upside (overvalued).
What is the fair value of CAMLINFINE?
Our model-based fair value for Camlin Fine Sciences Limited is ₹24.45 (as of Sep 27, 2026), built from audited fundamentals. The current price: ₹97.30.
What is the quality score of CAMLINFINE?
Camlin Fine Sciences Limited has a Quality Score of 31/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Camlin Fine Sciences Limited (CAMLINFINE)?
Our model-based price target is the fair value of ₹24.45 (as of Sep 27, 2026) from 15 valuation models. Cautious scenario ₹19.20, optimistic scenario ₹30.56. It is a calculation from audited fundamentals, not an analyst target.
What is the Camlin Fine Sciences Limited stock forecast for 2026?
Our models put fair value at ₹24.45, about −75% upside versus a price of ₹97.30 (overvalued). Cautious scenario ₹19.20, optimistic scenario ₹30.56. The calculation is refreshed regularly with new filings.
What is the revenue of Camlin Fine Sciences Limited (CAMLINFINE)?
Camlin Fine Sciences Limited reported trailing-twelve-month revenue of about ₹17.2B (latest available figure, as of Sep 27, 2026).
What is the intrinsic value of Camlin Fine Sciences Limited (CAMLINFINE)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Camlin Fine Sciences Limited it is ₹24.45 per share (as of Sep 27, 2026), against a price of ₹97.30. It is the blended result of 15 valuation models (cash flow, earnings, asset, dividend).
Is Camlin Fine Sciences Limited stock overvalued or undervalued in 2026?
As of Sep 27, 2026, CAMLINFINE trades above its calculated fair value: price ₹97.30, fair value ₹24.45, a gap of about −75% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of CAMLINFINE?
No. The price is what the market pays today (₹97.30); the fair value is what the company's own numbers justify (₹24.45). For Camlin Fine Sciences Limited the two are ₹72.85 per share apart. That gap is exactly why we show both numbers side by side.
How much is Camlin Fine Sciences Limited worth?
The market values Camlin Fine Sciences Limited at about ₹26.1B (market capitalisation, as of Sep 27, 2026). Per share that is ₹97.30; our models calculate a fair value of ₹24.45 per share.
What do the bullish and bearish scenarios say about CAMLINFINE?
Our models span a range for Camlin Fine Sciences Limited: cautious scenario ₹19.20, base ₹24.45, optimistic ₹30.56 per share (as of Sep 27, 2026, price ₹97.30). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of Camlin Fine Sciences Limited (CAMLINFINE)?
Balance-sheet figures for Camlin Fine Sciences Limited (as of Sep 27, 2026): return on equity −3.4%, debt of 0.29 per unit of equity. They feed the Quality Score of 31/100, which measures business quality independently of the share price.
How far is CAMLINFINE from its 52-week high?
Camlin Fine Sciences Limited trades at ₹97.30, about 56% below its 52-week high of ₹219.23 and 1% above the low of ₹96.45 (as of Sep 25, 2026). Distance from the high says nothing about value: that is what the fair value of ₹24.45 is for.
Which stocks are comparable to Camlin Fine Sciences Limited?
From the same area (Basic Materials) we also value Linde plc, The Sherwin-Williams Company, Ecolab Inc, Air Products and Chemicals, Inc, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Camlin Fine Sciences Limited stock attractive at the current price?
The data as of Sep 27, 2026: price ₹97.30, calculated fair value ₹24.45 (−75%), Quality Score 31/100, from 15 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of CAMLINFINE calculated?
We run Camlin Fine Sciences Limited through 15 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of ₹24.45, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 16.2 % above its aggregate fair value. Camlin Fine Sciences Limited itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Camlin Fine Sciences Limited (CAMLINFINE)?
The closing price on Sep 25, 2026 was ₹97.30. Our model-based fair value is ₹24.45, about −75% upside (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Camlin Fine Sciences Limited right now?
The price sits above even our optimistic bull case (₹30.56). The favourable scenario is already priced in. Weak quality (31/100) and above fair value at the same time, the margin of safety is missing on both counts.
Key figures of Camlin Fine Sciences Limited
How large is the market capitalisation of Camlin Fine Sciences Limited (CAMLINFINE)?
The market capitalisation of Camlin Fine Sciences Limited is ₹26.1B (≈ $273M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Camlin Fine Sciences Limited (CAMLINFINE)?
The price-to-sales ratio of Camlin Fine Sciences Limited is 1.52 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Camlin Fine Sciences Limited (CAMLINFINE)?
Earnings per share at Camlin Fine Sciences Limited are ₹−1.60. Earnings per share over the last twelve months: total profit spread across every single share.
What is the net margin of Camlin Fine Sciences Limited (CAMLINFINE)?
The net margin of Camlin Fine Sciences Limited is 1.6% (fiscal year 2026). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Camlin Fine Sciences Limited (CAMLINFINE)?
The return on equity (ROE) of Camlin Fine Sciences Limited is −3.4% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Camlin Fine Sciences Limited (CAMLINFINE)?
On an EBIT basis the return on assets of Camlin Fine Sciences Limited is 5.2% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Camlin Fine Sciences Limited (CAMLINFINE)?
The operating margin of Camlin Fine Sciences Limited is 0.1% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Camlin Fine Sciences Limited (CAMLINFINE)?
Revenue at Camlin Fine Sciences Limited is growing −2.9% versus a year earlier (3y avg +0.8%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Camlin Fine Sciences Limited (CAMLINFINE)?
Earnings per share at Camlin Fine Sciences Limited are growing +154% versus a year earlier. How much earnings per share grew versus a year earlier.
How much free cash flow does Camlin Fine Sciences Limited (CAMLINFINE) generate?
The free cash flow of Camlin Fine Sciences Limited is −₹331M (fiscal year 2026). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net debt does Camlin Fine Sciences Limited (CAMLINFINE) carry?
The net debt of Camlin Fine Sciences Limited is ₹5.7B (fiscal year 2026). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed
Watch Camlin Fine Sciences Limited in the live analysis
One click puts Camlin Fine Sciences Limited on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.
